Assignee

IBC PHARMACEUTICALS INC

US·49 granted patents·15 pending applications·2,076 citations·filing 2002–2019

Technology mixC07K64 A61K62 A61P40 B82Y27 C12N19 C12Y18

Top patents by PatentIndex Score

64 records

0199US8349332B2Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseasesIBC PHARMACEUTICALS INC·Filed 2011·Granted Jan 8, 2013·58 cites·12 claims
0299US8034352B2Tetrameric cytokines with improved biological activityIBC PHARMACEUTICALS INC·Filed 2010·Granted Oct 11, 2011·61 cites·6 claims
0399US7906121B2Methods and compositions for generating bioactive assemblies of increased complexity and usesIBC PHARMACEUTICALS INC·Filed 2009·Granted Mar 15, 2011·125 cites·25 claims
0499US7906118B2Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technologyIBC PHARMACEUTICALS INC·Filed 2009·Granted Mar 15, 2011·90 cites·17 claims
0599US7901680B2Dock-and-lock (DNL) vaccines for cancer therapyIBC PHARMACEUTICALS INC·Filed 2009·Granted Mar 8, 2011·92 cites·19 claims
0699US7666400B2PEGylation by the dock and lock (DNL) techniqueIBC PHARMACEUTICALS INC·Filed 2007·Granted Feb 23, 2010·158 cites·21 claims
0799US7550143B2Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and usesIBC PHARMACEUTICALS INC·Filed 2006·Granted Jun 23, 2009·177 cites·21 claims
0899US7534866B2Methods and compositions for generating bioactive assemblies of increased complexity and usesIBC PHARMACEUTICALS INC·Filed 2006·Granted May 19, 2009·287 cites·18 claims
0999US7527787B2Multivalent immunoglobulin-based bioactive assembliesIBC PHARMACEUTICALS INC·Filed 2006·Granted May 5, 2009·293 cites·23 claims
1099US7521056B2Stably tethered structures of defined compositions with multiple functions or binding specificitiesIBC PHARMACEUTICALS INC·Filed 2006·Granted Apr 21, 2009·297 cites·28 claims
1198US9382329B2Disease therapy by inducing immune response to Trop-2 expressing cellsIBC PHARMACEUTICALS INC·Filed 2015·Granted Jul 5, 2016·23 cites·15 claims
1298US9315567B2T-cell redirecting bispecific antibodies for treatment of diseaseIBC PHARMACEUTICALS INC·Filed 2013·Granted Apr 19, 2016·47 cites·10 claims
1398US8003111B2Dimeric alpha interferon pegylated site-specifically shows enhanced and prolonged efficacy in vivoIBC PHARMACEUTICALS INC·Filed 2010·Granted Aug 23, 2011·71 cites·10 claims
1498US7981398B2PEGylation by the dock and lock (DNL) techniqueIBC PHARMACEUTICALS INC·Filed 2009·Granted Jul 19, 2011·58 cites·25 claims
1598US7871622B2Stably tethered structures of defined compositions with multiple functions or binding specificitiesIBC PHARMACEUTICALS INC·Filed 2009·Granted Jan 18, 2011·74 cites·14 claims
1698US7858070B2Multivalent immunoglobulin-based bioactive assembliesIBC PHARMACEUTICALS INC·Filed 2009·Granted Dec 28, 2010·71 cites·12 claims
1796US9670286B2Disease therapy by inducing immune response to Trop-2 expressing cellsIBC PHARMACEUTICALS INC·Filed 2016·Granted Jun 6, 2017·9 cites·14 claims
1895US10111954B2Combination therapy for inducing immune response to diseaseIBC PHARMACEUTICALS INC·Filed 2016·Granted Oct 30, 2018·8 cites·13 claims
1995US9682143B2Combination therapy for inducing immune response to diseaseIBC PHARMACEUTICALS INC·Filed 2013·Granted Jun 20, 2017·18 cites·13 claims
2093US10662252B2Disease therapy by inducing immune response to Trop-2 expressing cellsIBC PHARMACEUTICALS INC·Filed 2017·Granted May 26, 2020·5 cites·7 claims
2192US10131712B2Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitorsIBC PHARMACEUTICALS INC·Filed 2017·Granted Nov 20, 2018·5 cites·22 claims
2292US8871216B2Multiple signaling pathways induced by hexvalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseasesIBC PHARMACEUTICALS INC·Filed 2012·Granted Oct 28, 2014·9 cites·17 claims
2391US10245321B2Combination therapy for inducing immune response to diseaseIBC PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·3 cites·8 claims
2491US9931413B2Tetrameric cytokines with improved biological activityIBC PHARMACEUTICALS INC·Filed 2016·Granted Apr 3, 2018·6 cites·6 claims
2591US9879088B2Disease therapy by inducing immune response to Trop-2 expressing cellsIBC PHARMACEUTICALS INC·Filed 2017·Granted Jan 30, 2018·4 cites·8 claims
2691US9272029B2Interferon lambada-antibody complexesIBC PHARMACEUTICALS INC·Filed 2013·Granted Mar 1, 2016·7 cites·6 claims
2789US8883162B2Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumorsIBC PHARMACEUTICALS INC·Filed 2012·Granted Nov 11, 2014·7 cites·20 claims
2886US10022427B2Interferon lambda-antibody complexesIBC PHARMACEUTICALS INC·Filed 2016·Granted Jul 17, 2018·4 cites·17 claims
2985US9550838B2Dock-and-lock (DNL) complexes for therapeutic and diagnostic useIBC PHARMACEUTICALS INC·Filed 2014·Granted Jan 24, 2017·3 cites·1 claims
3081US9416197B2Bispecific antibodies that neutralize both TNF-α and IL-6: novel therapeutic agent for autoimmune diseaseIBC PHARMACEUTICALS INC·Filed 2014·Granted Aug 16, 2016·1 cites·12 claims
3179US9359443B2Combination therapy with anti-CD74 and anti-CD20 antibodies provides enhanced toxicity to B-cell diseasesIBC PHARMACEUTICALS INC·Filed 2014·Granted Jun 7, 2016·1 cites·4 claims
3278US8906378B2Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseasesIBC PHARMACEUTICALS INC·Filed 2013·Granted Dec 9, 2014·2 cites·7 claims
3374US9540435B2Stably tethered structures of defined compositions with multiple functions or binding specificitiesIBC PHARMACEUTICALS INC·Filed 2014·Granted Jan 10, 2017·1 cites·8 claims
3473US9737617B2Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseasesIBC PHARMACEUTICALS INC·Filed 2014·Granted Aug 22, 2017·0 cites·17 claims
3572US9446123B2Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacyIBC PHARMACEUTICALS INC·Filed 2013·Granted Sep 20, 2016·1 cites·2 claims
3671US9169470B2Methods and compositions for generating bioactive assemblies of increased complexity and usesIBC PHARMACEUTICALS INC·Filed 2014·Granted Oct 27, 2015·0 cites·5 claims
3770US10385139B2Murine, chimeric, humanized or human anti-TNF-alpha antibodiesIBC PHARMACEUTICALS INC·Filed 2018·Granted Aug 20, 2019·0 cites·10 claims
3869US9932413B2Murine, chimeric, humanized or human anti-IL-6 antibodiesIBC PHARMACEUTICALS INC·Filed 2017·Granted Apr 3, 2018·0 cites·3 claims
3968US2019142939A1Combination therapy for inducing immune response to diseaseIBC PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
4066US9540618B2Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and usesIBC PHARMACEUTICALS INC·Filed 2014·Granted Jan 10, 2017·0 cites·4 claims
4165US9498542B2Tetrameric cytokines with improved biological activityIBC PHARMACEUTICALS INC·Filed 2013·Granted Nov 22, 2016·0 cites·6 claims
4264US10183992B2T-cell redirecting bispecific antibodies for treatment of diseaseIBC PHARMACEUTICALS INC·Filed 2017·Granted Jan 22, 2019·0 cites·6 claims
4364US9862770B2Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumorsIBC PHARMACEUTICALS INC·Filed 2014·Granted Jan 9, 2018·0 cites·27 claims
4463US10239938B2T-cell redirecting bispecific antibodies for treatment of diseaseIBC PHARMACEUTICALS INC·Filed 2016·Granted Mar 26, 2019·0 cites·5 claims
4563US2016311931A1Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune diseaseIBC PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
4662US9872920B2PEGylation by the dock and lock (DNL) techniqueIBC PHARMACEUTICALS INC·Filed 2016·Granted Jan 23, 2018·0 cites·13 claims
4762US2015374846A1Methods and Compositions for Generating Bioactive Assemblies of Increased Complexity and UsesIBC PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
4861US9248184B2Dock-and-lock (DNL) constructs for human immunodeficiency virus (HIV) therapyIBC PHARMACEUTICALS INC·Filed 2013·Granted Feb 2, 2016·0 cites·9 claims
4961US2016361405A1Dock-and-Lock (DNL) Vaccines for Cancer TherapyIBC PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
5060US10308688B2T-cell redirecting bispecific antibodies for treatment of diseaseIBC PHARMACEUTICALS INC·Filed 2016·Granted Jun 4, 2019·0 cites·11 claims

Showing the top 50 of 64 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when IBC PHARMACEUTICALS INC files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →